Results 191 to 200 of about 26,125 (257)

Transitioning CAR‐T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta‐cel in Germany

open access: yes
HemaSphere, Volume 10, Issue 7, July 2026.
Christof Scheid   +6 more
wiley   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

open access: yesThe FEBS Journal, Volume 293, Issue 13, Page 3899-3953, July 2026.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard   +4 more
wiley   +1 more source

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T‐Cell Immunotherapy for B‐Cell Malignancies: A Case Series

open access: yes
Hematological Oncology, Volume 44, Issue 4, July 2026.
Gianluca Cavallaro   +12 more
wiley   +1 more source

Navigating the Future of Respiratory Infections: Key Insights From International Congress in Singapore, 17–20 September 2025

open access: yesInfluenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background The 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17–20 September 2025), examined evolving approaches to prevention and management of respiratory infections.
Narmadha Morvil   +5 more
wiley   +1 more source

Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers. [PDF]

open access: yesDiscov Oncol
Ardah MT   +8 more
europepmc   +1 more source

Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series. [PDF]

open access: yesAnn Hematol
Della Pepa R   +7 more
europepmc   +1 more source

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. [PDF]

open access: yesSignal Transduct Target Ther
Ding Z   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy